An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

• Status: Completed
• Trial end date: 2020-05-27
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kathy Miller
• Treatments: Gedatolisib

Criteria

Inclusion Criteria:

• Metastatic Triple-negative Breast Cancer

• Willingness to undergo tumor biopsy

• Patients must have received at least 1 prior chemotherapy regimen for metastatic disease

Exclusion Criteria:

• Previous treatment with mTOR inhibitor

• Untreated brain metastases